Literature DB >> 438333

Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.

R M Carey, M O Thorner, E M Ortt.   

Abstract

This study was designed to investigate the possible role of dopaminergic mechanisms in the control of the renin-angiotensin-aldosterone system in normal man. Six normal male subjects in metabolic balance at 150 meq sodium, 60 meq potassium constant intake received the specific dopamine antagonist, metoclopramide, 10 mg i.v. or placebo followed by angiotensin II infusion 1 h later on 2 consecutive days. Metoclopramide increased plasma aldosterone concentration from 8.2+/-2.2 to 21.0+/-3.3 ng/100 ml (P < 0.005) and plasma prolactin concentration from 18.0+/-4.0 to 91.7+/-4.0 ng/ml (P < 0.001) within 15 min of its administration. At 1 h, plasma aldosterone and prolactin concentrations remained elevated at 16.8+/-2.1 ng/100 ml (P < 0.01) and 86.8+/-15.9 ng/ml (P < 0.005), respectively. Angiotensin II at 2, 4, and 6 pmol/kg per min further increased plasma aldosterone concentration to 27.2+/-3.4, 31.9+/-5.7, and 36.0+/-6.7 ng/100 ml (P < 0.02), respectively. Placebo did not alter plasma aldosterone or prolactin concentrations, but angiotensin II increased plasma aldosterone concentration to 13.7+/-2.4, 19.0+/-1.9, and 23.3+/-3.2 ng/100 ml (P < 0.005). The increment of plasma aldosterone concentration in response to angiotensin II was similar after metoclopramide or placebo. The six subjects also received the dopamine agonist, bromocriptine, 2.5 mg or placebo at 6 p.m., midnight, and 6 a.m. followed by angiotensin II infusion on 2 consecutive d. Bromocriptine suppressed prolactin to <3 ng/ml. After placebo, plasma aldosterone concentration increased from 5.2+/-1.4 to 12.3+/-1.7, 17.2+/-2.2, and 21.8+/-3.5 ng/100 ml (P < 0.01) and after bromocriptine from 7.2+/-1.0 to 14.7+/-3.0, 19.8+/-3.2, and 23.4+/-1.6 ng/100 ml (P < 0.001) with each respective angiotensin II dose. No difference in the response to angiotensin II after bromocriptine or placebo was observed. Plasma renin activity, free 11-hydroxycorticoid concentration, and serum potassium concentration were unchanged by metoclopramide or bromocriptine. The results suggest that aldosterone production is under maximum tonic dopaminergic inhibition which can be overridden with stimulation by angiotensin II in normal man.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438333      PMCID: PMC372008          DOI: 10.1172/JCI109356

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma.

Authors:  D MATTINGLY
Journal:  J Clin Pathol       Date:  1962-07       Impact factor: 3.411

2.  Gustatory-alimentary reflex inhibition of aldosterone hypersecretion by the autotransplanted adrenal gland of sodium deficient sheep.

Authors:  D A Denton; J R Blair-West; J P Coghlan; B A Scoggins; R D Wright
Journal:  Acta Endocrinol (Copenh)       Date:  1977-01

3.  Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome.

Authors:  M Goldstein; A Lieberman; A F Battista; J Y Lew; Y Matsumoto
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1978

4.  Cardiovascular actions of bromocriptine.

Authors:  B J Clark; G Scholtysik; E Flückiger
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1978

5.  Effect of metoclopramide-induced prolactin on aldosterone secretion in normal subjects.

Authors:  T Ogihara; S Matsumura; T Onishi; K Miyai; T Uozumi
Journal:  Life Sci       Date:  1977-02-01       Impact factor: 5.037

6.  Evidence against prolactin stimulation of aldosterone in normal human subjects and patients with primary aldosteronism, including a patient with primary aldosteronism and a prolactin-producing pituitary microadenoma.

Authors:  O B Holland; C E Gomez-Sanchez; D C Kem; M H Weinberger; N J Kramer; J R Higgins
Journal:  J Clin Endocrinol Metab       Date:  1977-11       Impact factor: 5.958

7.  Dopamine as a possible neurotransmitter in gastric relaxation.

Authors:  J E Valenzuela
Journal:  Gastroenterology       Date:  1976-12       Impact factor: 22.682

8.  Metoclopramide increases plasma aldosterone concentration in man.

Authors:  G Norbiato; M Bevilacqua; U Raggi; P Micossi; C Moroni
Journal:  J Clin Endocrinol Metab       Date:  1977-12       Impact factor: 5.958

9.  Lack of effect of prolactin inhibition by alpha-bromoergocriptine (CB 154) on plasma aldosterone in anephric and non-nephrectomized patients on regular haemodialysis.

Authors:  K Olgaard; C Hagen; S Madsen; L Hummer
Journal:  Acta Endocrinol (Copenh)       Date:  1977-07

10.  Studies on the nature of thyroidal suppression during acute falciparum malaria: integrity of pituitary response to TRH and alterations in serum T3 and reverse T3.

Authors:  L Wartofsky; K D Burman; R C Dimond; G L Noel; A G Frantz; J M Earll
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

View more
  28 in total

1.  Aldosterone response to metoclopramide is mediated through the autonomic nervous system in man.

Authors:  D K Sommers; E C Meyer; M van Wyk; L S de Villiers
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man.

Authors:  P W de Leeuw; P N van Es; H A de Bruyn; W H Birkenhäger
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Effects of catecholamines on secretion of adrenocorticotrophic hormone (ACTH) in man.

Authors:  S Al-Damluji; L H Rees
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

4.  Effect of atrial peptides on aldosterone production.

Authors:  K Atarashi; P J Mulrow; R Franco-Saenz
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

5.  Domperidone treatment in man inhibits the fall in plasma renin activity induced by intravenous gamma-L-glutamyl-L-dopa.

Authors:  D P Worth; J N Harvey; J Brown; A Worral; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

6.  Primary tissue culture of human adrenocortical Conn's adenomata. Bromocriptine as a possible agonist-antagonist of angiotensin at the cellular level.

Authors:  U Armato; F Mantero
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

7.  Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension.

Authors:  G Bise; C Foletti; C Beretta-Piccoli; P Weidmann; W H Ziegler; R Mordasini; C Bachmann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failure.

Authors:  D du Cheyron; A Lesage; C Daubin; M Ramakers; P Charbonneau
Journal:  Intensive Care Med       Date:  2003-08-28       Impact factor: 17.440

9.  An investigation of the importance of the adrenal gland to the action of dopamine in the rat kidney.

Authors:  M J Akpaffiong; P H Redfern; B Woodward
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

10.  Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.

Authors:  R M Carey; M O Thorner; E M Ortt
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.